ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO603

Protective Effect of an Oral Adsorbent AST-120 on Podocyte Injury

Session Information

Category: Diabetes

  • 501 Diabetes Mellitus and Obesity: Basic - Experimental


  • Aoki, Rieko, KUREHA CORPORATION, Tokyo, Japan
  • Fujieda, Ayako, KUREHA CORPORATION, Tokyo, Japan
  • Ezawa, Atsuko, KUREHA CORPORATION, Tokyo, Japan
  • Iijima, Hiroko, KUREHA CORPORATION, Tokyo, Japan
  • Yamashita, Yusuke, KUREHA CORPORATION, Tokyo, Japan
  • Kikuchi, Kaori, KUREHA CORPORATION, Tokyo, Japan
  • Kato, Mariko, KUREHA CORPORATION, Tokyo, Japan
  • Itoh, Yoshiharu, KUREHA CORPORATION, Tokyo, Japan

Diabetic nephropathy is a major complication of diabetes and the leading cause of end-stage renal disease. An oral adsorbent AST-120 has been used clinically in Japan as a medicine for patients with chronic kidney disease (CKD) to slow down the progression of CKD. However, there is little evidence to support therapeutic efficacy of AST-120 for early stage overt diabetic nephropathy. Previously, we showed that the administration of AST-120 reduced the proteinuria and suppressed podocyte foot process effacement on SHR/NDmcr-cp (SHR/ND) rats, rodent model of metabolic syndrome/ type 2 diabetes. We also showed that AST-120 prevented the decrease of renal function and suppressed the levels of serum uremic toxins in unilateral nephrectomized (UNX) SHR/ND rats.
In this study, we investigated whether the renal tissues of UNX SHR/ND rats were ameliorated by the administration of AST-120 and whether uremic toxins induced deleterious effects on the cultured podocyte cells in vitro.


Male SHR/ND rats, aged 8 weeks, underwent either UNX (n=20) or sham (n=6) surgery under anesthesia. Half of UNX rats were administered 8% AST-120 for 30 weeks in their diet, and serum and 24-hour urine samples were collected for biomedical studies. The gene expression of podocyte markers and fibrosis makers by real-time PCR in renal tissues from UNX-SHR/ND rats treated with or without AST-120. In vitro study, we evaluated effects of uremic toxins on the cytotoxicity and reactive oxygen species (ROS) production of mouse podocyte cells.


AST-120-administered UNX-SHR/ND rats showed significantly lower levels of urinary protein excretion, serum creatinine, serum uremic toxins such as indole acetic acid (IAA) and kidney weight than UNX-SHR/ND rats. Nephrin, as a podocyte marker, in renal tissues was higher expressed in AST-120-administered UNX-SHR/ND rats than in UNX-SHR/ND rats. Plasminogen activator inhibitor-1 was lower expressed in AST-120-administered UNX SHR/ND rats. In vitro study, indoxy sulfate (IS) and IAA induced ROS production and the cytotoxicity of mouse podocyte cells, and N-acetyl-L-cysteine inhibited this effect.


These results indicate that the administration of AST-120 from the early stage of diabetic nephropathy has renoprotective effects. One of the mechanisms of the effect may be the reduction of uremic toxin by AST-120.